CRP and hs-CRP measure the same protein but answer different clinical questions. The standard C-Reactive Protein Test is commonly used to detect or follow a broader inflammatory response. The hs-CRP Test uses a high-sensitivity assay that measures much lower CRP concentrations with greater precision, allowing selected use in cardiovascular-risk assessment. Neither result identifies the source of inflammation, shows whether an artery is blocked, diagnoses heart disease, or rules out a heart attack. Infection, injury, surgery, and other acute inflammatory states can raise either result and may make an hs-CRP value unsuitable for long-term heart-risk interpretation.
This focused comparison is part of the Ulta Lab Tests Knowledge Center. Use the Heart Health Blood Tests guide for broader cardiovascular test selection and the Inflammation and Autoimmune Blood Tests guide for wider inflammatory and autoimmune questions. The Complete Guide to Lab Tests and Blood Work explains how individual tests, panels, screening, and monitoring differ.
| Feature | Standard CRP | hs-CRP |
|---|---|---|
| What it measures | C-reactive protein in blood | The same C-reactive protein in blood |
| Analytical focus | Broader inflammatory changes across a higher working range | Greater precision at the low concentrations used for cardiovascular-risk assessment |
| Common purpose | Support evaluation or monitoring of a general inflammatory process | Add inflammatory context to selected cardiovascular-risk discussions |
| Best timing | Depends on the inflammatory or monitoring question | When clinically stable and free of a known acute inflammatory illness |
| What a high result means | An inflammatory signal is present; the cause and location remain unknown | Systemic inflammation may add cardiovascular-risk information; the source may be noncardiac |
| Major limitation | Not disease-specific and not intended to classify low-level cardiovascular risk | Not heart-specific, not a plaque test, and easily influenced by acute illness |
C-reactive protein is an acute-phase protein made mainly by the liver. Its concentration can increase when immune signaling responds to infection, tissue injury, surgery, or inflammatory disease. A blood result therefore reflects a systemic inflammatory signal; it does not reveal where that signal began or which condition caused it.3
The “hs” in hs-CRP means high sensitivity. It does not mean that the person has more severe inflammation, that the CRP comes from the heart, or that hs-CRP measures a different molecule. The high-sensitivity assay is designed to quantify low baseline CRP concentrations more precisely. That analytical precision—not a different specimen or a different protein—is what makes it useful for cardiovascular-risk context.5
Standard CRP is commonly used when the question is whether a broader inflammatory response may be present or changing. Depending on the clinical setting, it may support:
A higher standard CRP does not distinguish a viral infection from a bacterial infection, identify a specific autoimmune disease, or prove that symptoms are inflammatory. A low value does not exclude every inflammatory condition. The result must be combined with the reason for testing, symptoms, examination findings, other laboratory results, medications, and the change over time.
hs-CRP can add information about low-level systemic inflammation associated with future atherosclerotic cardiovascular events. It is an adjunct—not a replacement—for age, blood pressure, cholesterol, diabetes status, kidney health, tobacco exposure, family history, and an appropriate cardiovascular-risk estimate.
The 2026 ACC/AHA dyslipidemia guideline gives hs-CRP a specific, selective role. For an adult without known atherosclerotic cardiovascular disease whose 10-year PREVENT-ASCVD risk is borderline at 3% to less than 5%, an hs-CRP of at least 2 mg/L on two successive occasions, with no identifiable underlying cause for the elevation, can function as a risk enhancer in a clinician-patient discussion.1 This is not a universal screening instruction or a diagnosis.
Guidelines answer different questions. The U.S. Preventive Services Task Force has found insufficient evidence to determine the overall benefit and harm of routinely adding hs-CRP to traditional cardiovascular-risk assessment for all asymptomatic adults.4 Taken together, the evidence supports focused use when the result is likely to change a decision—not automatic testing for everyone.
Start with the exact test name, unit, laboratory reference interval or interpretive note, and reason the test was ordered. CRP may be reported in milligrams per liter (mg/L) or milligrams per deciliter (mg/dL). One mg/dL equals 10 mg/L, but converting units does not make a standard CRP assay interchangeable with an hs-CRP assay.
There is no single standard-CRP number that diagnoses infection, an autoimmune disease, or another inflammatory condition. Laboratories may use different methods and reporting intervals. The magnitude of elevation, the clinical setting, related findings, and the direction of change are more useful than attaching one disease label to one value.
| Result or framework | How it may be used | Important caution |
|---|---|---|
| Below 1 mg/L | Commonly described as lower relative cardiovascular risk within this marker's framework | Does not rule out plaque or erase other cardiovascular risk factors |
| 1 to 3 mg/L | Commonly described as average or intermediate relative cardiovascular risk | Not a diagnosis and not a treatment target by itself |
| Above 3 mg/L | Commonly described as higher relative cardiovascular risk when the person is clinically stable | Look for acute or noncardiac inflammatory explanations |
| At least 2 mg/L on two successive occasions | A 2026 ACC/AHA risk enhancer when measured in the guideline's selected borderline-risk setting and no other cause is identified | This decision threshold overlaps the traditional categories and serves a different purpose |
| Above 10 mg/L | May reflect infection or another acute-phase response rather than a stable cardiovascular baseline | The 2025 ACC scientific statement advises repeating in 2 to 3 weeks and using the lower value, not the average, for risk prediction |
The below-1, 1-to-3, and above-3 mg/L categories describe relative cardiovascular risk. The at-least-2 mg/L threshold in the 2026 guideline is a risk-enhancer criterion for a defined clinical situation. These frameworks overlap because they answer different questions; neither is a stand-alone heart-disease diagnosis.12
For a broader explanation of flags, units, reference intervals, decision thresholds, and trends, see How to Read and Understand Your Lab Results.
CRP is designed to respond to inflammation. That makes it useful, but it also means the result is vulnerable to temporary influences. An infection, fever, recent injury, surgery, tissue inflammation, or active inflammatory-disease flare can raise standard CRP and hs-CRP. Smoking, obesity, pregnancy, hormone therapy, and some medicines may also affect the baseline or its interpretation.36
An elevated hs-CRP during an acute illness does not show that inflammation came from the arteries. It may simply reflect the current illness. Conversely, a low hs-CRP does not prove that the cardiovascular system is healthy. The test adds one piece to a larger risk assessment.
Repeat testing should answer a defined question rather than follow an automatic schedule. It may be appropriate when:
Do not average results collected under very different health conditions and assume the average represents a true baseline. A changing value also should not trigger a medication or supplement change without professional review.
Inflammation participates in atherosclerosis, but CRP is not a picture of the arteries. Neither standard CRP nor hs-CRP can:
Do not use outpatient CRP testing for acute symptoms. New chest pressure or pain, severe shortness of breath, fainting, sudden one-sided weakness, facial droop, or speech difficulty requires immediate emergency evaluation. Do not wait for a CRP or hs-CRP result.
Educational framework—not a diagnostic or treatment algorithm.
| Question or situation | More relevant test | Why |
|---|---|---|
| Is a broad inflammatory process present or changing? | Standard CRP | Designed for general inflammatory evaluation or monitoring in context |
| Could low-level inflammation refine a preventive cardiovascular-risk discussion? | hs-CRP | Provides better precision at low CRP concentrations when the person is clinically stable |
| Are there acute chest or stroke-like symptoms? | Neither as an outpatient test | Urgent evaluation is needed; CRP cannot rule out an emergency |
| Should a previous result be trended? | Usually the same assay | Comparable method, units, laboratory, timing, and health status make a trend easier to interpret |
The current Ulta Lab Tests pages for the individual standard CRP and hs-CRP tests state that no special preparation is required. Fasting is not required for either individual test. If CRP or hs-CRP is ordered as part of a panel containing other biomarkers, follow the preparation instructions for the entire order.
Choose the test that matches the question rather than treating a larger panel as automatically better. To understand ordering, preparation, specimen collection, result delivery, and responsible follow-up, review Direct-Access Lab Testing: How It Works and What to Expect.
They measure the same protein. The difference is the assay's precision and intended use. Standard CRP is commonly used for broader inflammatory evaluation, while hs-CRP measures low concentrations more precisely for selected cardiovascular-risk assessment.
Not for every purpose. hs-CRP is more precise at low concentrations, which is useful for cardiovascular-risk context. Standard CRP is more appropriate for many general inflammation questions. Accuracy depends on using the correct assay for the clinical question.
No. A higher stable hs-CRP may add risk information, but it does not show plaque or arterial narrowing and cannot diagnose coronary artery disease. It must be interpreted with traditional risk factors and, when appropriate, examination or imaging.
Yes. Infection and other acute inflammatory states can raise hs-CRP, sometimes substantially. A value collected while ill may not represent a stable cardiovascular baseline, so repeat testing after recovery may be appropriate.
Timing depends on why it was ordered. The 2025 ACC scientific statement advises repeating values above 10 mg/L in 2 to 3 weeks for cardiovascular-risk prediction. The 2026 ACC/AHA risk-enhancer criterion also relies on values of at least 2 mg/L on two successive occasions without another identifiable cause.
The current Ulta Lab Tests pages for the two individual tests state that no special preparation is required. If either marker is part of a panel, follow the instructions for the full panel because another component may require fasting or specific timing.
Not necessarily. A low result is favorable within its narrow inflammatory context, but it does not cancel risk related to cholesterol, high blood pressure, diabetes, smoking, kidney disease, family history, or existing plaque.
Do not assume so. Although both assays measure CRP and their numerical ranges may overlap, standard CRP is not intended to provide the same low-concentration precision or cardiovascular interpretation as hs-CRP. Confirm the assay used.
“Cardiac CRP,” “cardio CRP,” and “high-sensitivity CRP” commonly refer to hs-CRP. Check the exact test name and report because informal labels can vary.
Medicines, supplements, and hormone therapy can influence CRP or its interpretation. Share a complete list with the healthcare professional reviewing the result. Do not stop or change a prescription based only on a CRP value or an online article.
The central difference in CRP vs. hs-CRP is not the protein being measured—it is the assay's sensitivity and intended use. Standard CRP supports broader inflammatory evaluation and monitoring. hs-CRP can add low-level inflammatory context to selected cardiovascular-risk discussions when measured during a stable period. Neither test identifies the source of inflammation or diagnoses heart disease.
Before testing, define the question, choose the matching assay, review preparation for the exact order, and plan how an abnormal or unexpected result will be interpreted. A result is most useful when considered with symptoms, history, medications, traditional cardiovascular risk factors, related testing, and qualified professional guidance.
Medical note: This article is educational and does not provide individual diagnosis or treatment. Severe, sudden, or rapidly worsening symptoms require prompt professional or emergency evaluation.
Commercial disclosure: Ulta Lab Tests offers laboratory-testing services and may link to tests or panels discussed on this page. This content is educational and does not provide individual diagnosis or treatment.
Broader inflammatory evaluation and monitoring
Cardiovascular-risk refinement
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
